Literature DB >> 19823036

Uniquely modified RNA oligonucleotides targeting STAT3 suppress melanoma growth both in vitro and in vivo.

Lifang Yang1, Xiaoqian Ma, Lanbo Xiao, Min Tang, Xinxian Weng, Lunquan Sun, Ya Cao.   

Abstract

Signal transducers and activators of transcription-3 (STAT3), a central cytoplasmic transcription factor, is frequently overexpressed and constitutively activated during malignant transformation. The overexpression of STAT3 in melanoma cells is often observed and is suggested to be involved in tumorigenesis and development. In this study, a novel antisense RNA oligonucleotides targeting the STAT3 mRNA was 2'-O-methyl modified with a 3'-butanol tag was designed, and found this uniquely modified strategy dramatic increased the stability of the RNA oligonucleotides. The results showed that the RNA oligonucleotides, namely STT-33 and STT-34, strongly inhibited the target gene expression in the melanoma cells and resulted in increase cell apoptosis. Furthermore, the RNA oligonucleotides could significantly inhibit melanoma cell proliferation and xenografts growth in nude mice. Thus, the novel modified RNA oligonucleotides targeting STAT3 may serve as a useful tool to study the involvement of STAT3 in melanoma and potentially as an anti-cancer agent for melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19823036     DOI: 10.4161/cbt.8.21.9839

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  2 in total

Review 1.  An overview of gene therapy in head and neck cancer.

Authors:  Amit Bali; Deepika Bali; Ashutosh Sharma
Journal:  Indian J Hum Genet       Date:  2013-07

2.  In Vitro Evaluation of the Antimicrobial Ability and Cytotoxicity on Two Melanoma Cell Lines of a Benzylamide Derivative of Maslinic Acid.

Authors:  Ioana Zinuca Pavel; Corina Danciu; Camelia Oprean; Cristina Adriana Dehelean; Delia Muntean; René Csuk; Danina Mirela Muntean
Journal:  Anal Cell Pathol (Amst)       Date:  2016-12-05       Impact factor: 2.916

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.